CoChat

Gene therapy approval for Duchenne muscular dystrophy: a European perspective

Jolly, Hannah, Aartsma-Rus, Annemieke, Bertini, Enrico, De Waele, Liesbeth, Haberlova, Jana, Klein, Andrea, Niks, Erik, Servais, Laurent · 2025 · The Lancet
Cited by 11

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(25)00717-2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 9

  1. Shin, 2013, Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy, Mol Ther, 21, 750, 10.1038/mt.2012.283 · DOI · Paper page
  2. Mendell, 2023, A phase 2 clinical trial evaluating the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in patients with Duchenne muscular dystrophy (DMD) (S48.004), Neurology, 100, 10.1212/WNL.0000000000202973 · doi:10.1212/wnl.0000000000202973
  3. Mendell, 2025, AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial, Nat Med, 31, 332, 10.1038/s41591-024-03304-z · DOI · Paper page
  4. Muntoni, 2024, CIFFREO, a phase 3, randomized, double-blind, placebo-controlled study of fordadistrogene movaparvovec (FM) in ambulatory participants with Duchenne muscular dystrophy (DMD), Neuromuscul Disord, 43
  5. Ayyar Gupta, 2023, Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy, PLoS One, 18, 10.1371/journal.pone.0283669 · DOI
  6. Muntoni, 2019, Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy, PLoS One, 14, 10.1371/journal.pone.0221097 · DOI
  7. Stimpson, 2024, Quantifying variability in motor function in Duchenne muscular dystrophy: UK centiles for the North Star Ambulatory Assessment, 10 m walk run velocity and rise from floor velocity in GC treated boys, J Neuromuscul Dis, 11, 153, 10.3233/JND-230159 · doi:10.3233/jnd-230159
  8. Relaix, 2021, Perspectives on skeletal muscle stem cells, Nat Commun, 12, 692, 10.1038/s41467-020-20760-6 · DOI · Paper page
  9. Horton, 2022, A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment, J Neurol Neurosurg Psychiatry, 93, 1276

Cited by

See all 11

Metadata

Authors
Jolly, H., Aartsma-Rus, A., Bertini, E., De Waele, L., Haberlova, J., Klein, A., Niks, E., & Servais, L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2025-05
Volume
405
Issue
10489
Pages
1572-1573
ISSN
0140-6736
Cited by
11
References
4
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy approval for Duchenne muscular dystrophy: a European perspective. https://app.cochat.ai/papers/10.1016/s0140-6736(25)00717-2
The paper
Jolly, H., Aartsma-Rus, A., Bertini, E., De Waele, L., Haberlova, J., Klein, A., Niks, E., & Servais, L. (2025). Gene therapy approval for Duchenne muscular dystrophy: a European perspective. The Lancet. https://doi.org/10.1016/s0140-6736(25)00717-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.